Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10815211		
Filing Date		2004-03-31		
irst Named Inventor Hiroa		aki Kashima, et al.		
Art Unit		2641		
Examiner Name				
Attorney Docket Number		JP920030090US1		

				U.S.	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1								
	2								
If you wis	h to a	dd additional U.S. Pate	ent citatio	n information pl	ease click the	Add button.	_	Add	_
			U.S.P	ATENT APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document		Releva	Columns,Lines where int Passages or Relev s Appear	
	1								
If you wis	h to a	l dd additional U.S. Pub	lished Ap	plication citation	n information	please click the Ad	d button	Add	
				FOREIGN PAT	TENT DOCUM	MENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Publication Date	Applicant of cited		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	т.
	1	PUPA10-171490			1998-06-26	Takezawa Toshiyu al.	iki, et		С
	2	PUPA10-198395			1998-07-31	Masataki Hirokazu	, et al.		С

#### 

	3	PUPA2002-229585			2002-08-16	Abe Yoshiharu, et al.		
	4	PUPA2000-293196			2000-10-20	Hanazawa Takeshi		
	5	PUPA05-281989			1993-10-29	Nagata Masaaki, et al.		
	6	PUPA11-259089			1999-09-24	Tanigaki Koichi, et al.		
	7	PUPA64-055597			1989-03-02	Morii HideJi		
	8	PUPA2003-242147			2003-08-29	Nishitani Masanobu, et al.		
If you wis	h to ac	dd additional Foreign P	atent Document	citation	information pl	ease click the Add buttor		
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposisim, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					Тs			
	1							
If you wish to add additional non-patent literature document citation information please click the Add button Add								
EXAMINER SIGNATURE								
Examiner	Signa	ture				Date Considered		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10815211	
	Filing Date		2004-03-31	
	First Named Inventor Hiros		aki Kashima, et al.	
	Art Unit		2641	
	Examiner Name			
	Attorney Docket Numb	er	JP920030090US1	

See finit Codes of USPTO Patient Documents at your USPTO, CODY on MEPP 901.04. \* Exister office in all assets for elocurants, by the loss letter code (WPO) Standard 51.3. \* \*Projectioned person of the patient obscured for the patient obscured for the patient obscured for the patient obscured. \* How do not convert by the appropriate symbols as indicated on the document with PO Standard 51.16 if possible. \* Applicant is to place a check mark here if English targular strandards an attacked.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10815211			
Filing Date		2004-03-31			
First Named Inventor	Hiroaki Kashima, et al.				
Art Unit		2641			
Examiner Name					
Attorney Docket Number		JP920030090US1			

### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication of forms foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information sideologue statement. See 37 CFR 197(a)(1).

## OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.57(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
  - □ None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/HERMAN RODRIGUEZ/	Date (YYYY-MM-DD)	2006-08-24
Name/Drint	HERMAN PORRIGHEZ	Registration Number	53900

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 3T CFR. 11.4 This collection is estimated to take it hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. 0. Bot 1430, Alexandriu, V.S. 2213.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.231.1450.

# Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolline is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient of the patient application or patient. If you do not furnish the requested related to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may related that the patient process and/or examine your submission.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a pleath pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.